Group history

Our history

1929
1929_Romarene
Dr. Henri Beaufour creates Laboratoires Beaufour in Dreux (France) to launch Romarène®, a product derived from rosemary for the treatment of digestive disorders.
1954
1954_Citrate de Betaine
The Group launches Citrate de Betaïne®, a product used in the symptomatic treatment of dyspepsia.
1969
© Gerard UferasIPSEN LES ULYS 04_12_12
The Group opens its first research facility in Les Ulis (France).
1970
1970-Ginkor
The Group enters an expansion phase with the launch of Ginkor®, Tanakan® and Smecta®. The Group creates Laboratoires Ipsen (Institute of Synthetic Products from Natural Extraction).
1980
1980-decapeptyl
Ipsen initiates a partnership with Debiopharm....
1983
1983_Fondation
The Group creates La Fondation Ipsen under the aegis of the Fondation de France. Its mission is to foster interactions between leading scientists in the field of life sciences.
1992
Copyright davidpeart.com
Ipsen begins its development in China, with the opening of a representative office in Tianjin.
1994
1994_Dysport
Ipsen acquires Speywood, the company that developed Dysport® for the treatment of movement disorders and various forms of muscular spasticity.
1995
1995_Somatuline
The Group launches Somatuline®, its sustained-release peptide for the treatment of acromegaly and neuroendocrine tumors in France.
1996
1996_Forlax
Ipsen launches Forlax®, a product used for the treatment of constipation.
2000
2000_ChineSmecta
Ipsen opens a manufacturing facility in China to produce Smecta® for the Chinese market.
2001-2002
2001-2002_SomatulineAutogel
Ipsen launches Somatuline® Autogel® in the UK, France followed by many other countries, strengthening Ipsen’s competitive position. To the Group’s knowledge, Somatuline® Autogel® is the first semi-solid formulation for injection without any excipient, since the active substance controls the sustained release.
2003
2003_Teijin
Ipsen and Teijin enter into an agreement to develop and market four Ipsen products, notably Somatuline® Autogel®, in Japan and a Teijin product for the treatment of gout in Europe.
2004
ipsen
The Group opens a botulinum toxin manufacturing facility in Wrexham (United Kingdom).
2005
2005_IpsenEnBourse
Ipsen’s shares are listed on Euronext Paris. Ipsen enters into a licensing agreement with Radius through which Radius acquires the exclusive worldwide rights (excluding Japan) to develop, manufacture and distribute Ipsen’s osteoporosis proprietary molecule.
2006
2006-Tercica
Ipsen enters into an agreement with Medicis (now Valeant) to market its botulinum toxin in aesthetic medicine indications in the US, Canada and Japan.
2007
logo-ispen
The Group enters into a partnership with Galderma, for the development, promotion and distribution of the Group’s botulinum toxin type A in aesthetic medicine indications.
2008
2008_SalkInstitute
Ipsen initiates a partnership with the Salk Institute for Biological Studies (San Diego, US) aimed at improving understanding of proliferative and degenerative diseases.
2009
© Gerard UferasIPSEN WREXHAM  20_02_12
Ipsen and Galderma receive collective green light for Azzalure® from 15 European countries’ Health Authorities for the granting of national marketing authorizations for the treatment of glabellar lines
2010
Rhythm
Ipsen and Inspiration Biopharmaceuticals Inc. enter into a partnership to create a hemophilia franchise...
2011
© gerard UferasIpsen sige 17_12_10
Ipsen announces a new development strategy based on three pillars...
2012
2012-ActiveBiotech
Ipsen enters into a research partnership with Oncodesign to develop new therapeutic agents against LRRK2, a gene whose mutation is involved in Parkinson's disease.
2013
© Gerard UferasIPSEN 30_01_12SIGNE
Teijin Pharma Limited and Ipsen launch of Somatuline® 60/90/120 mg for subcutaneous injection in Japan for the treatment of acromegaly and pituitary gigantism.